Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
2018 · Nature · 1,331 citations
https://doi.org/10.1038/s41586-018-0130-2
M
Michael Fehlings
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
70
Papers
3.7K
Citations
20
h-index
26
i10-index
Michael Fehlings is an academic researcher from University Health Network. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 20, co-authored 60 publications.
ORCID: 0000-0002-0384-8408Papers by this author
worksOntogeny of different subsets of yellow fever virus-specific circulatory CXCR5+ CD4+ T cells after yellow fever vaccination
2020 · Scientific Reports · 9 citations
https://doi.org/10.1038/s41598-020-72610-6
The management of odontoid fractures through the lens of evolution in classification schemes: A systematic review with illustrative case examples
2025 · Brain and Spine · 6 citations
https://doi.org/10.1016/j.bas.2025.104205
AdV-ZFP-VEGF does not improve open-field walking (BBB) scores following SCI.
2015 · Figshare · 0 citations
https://doi.org/10.1371/journal.pone.0096137.g008
Additional file 6: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.9809597
Additional file 5: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.9809588
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat